Immunotherapy for multiple myeloma: new chances and hope

[1] Xia Jieyun,Li Hujun,Yan Zhiling,Zhou Dian,Wang Ying,Qi Yuekun,Cao Jiang,Li Depeng,Cheng Hai,Sang Wei,Zhu Feng,Sun Haiying,Chen Wei,Qi Kunming,Yan Dongmei,Qiu Tingting,Qiao Jianlin,Yao Ruosi,Liu Yang,Wang Xue,Zhang Yanlei,Peng Shuixiu,Huang ChihHua,Zheng Junnian,Li Zhenyu,Chang Alex H,Xu Kailin.Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial[J].Journal of clinical onco

[2] Dimopoulos Meletios A.,Dytfeld Dominik,Grosicki Sebastian,Moreau Philippe,Takezako Naoki,Hori Mitsuo,Leleu Xavier,LeBlanc Richard,Suzuki Kenshi,Raab Marc S.,Richardson Paul G.,Popa McKiver Mihaela,Jou Ying Ming,Yao David,Das Prianka,San Miguel Jesús.Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial[J].Journal of Clinical Oncology,2023

[3] Parikh Rujul H,Lonial Sagar.Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice[J].CA: a cancer journal for clinicians,2023

[4] Chari Ajai,Minnema Monique C.,Berdeja Jesus G.,Oriol Albert,van de Donk Niels W.C.J.,Rodríguez Otero Paula,Askari Elham,Mateos María Victoria,Costa Luciano J.,Caers Jo,Verona Raluca,Girgis Suzette,Yang Shiyi,Goldsmith Rachel B.,Yao Xiang,Pillarisetti Kodandaram,Hilder Brandi W.,Russell Jeffery,Goldberg Jenna D.,Krishnan Amrita.Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma[J].New England Journal of Medicine,2022

[5] Van De Donk Niels WCJ,Agha Mounzer,Cohen Adam D,Cohen Yael C,Anguille Sébastien,Kerre Tessa,Roeloffzen Wilfried W.H.,Schecter Jordan M,De Braganca Kevin C,Jackson Carolyn C,Varsos Helen,Mistry Pankaj,Roccia Tito,Xu Xiaoying,Li Katherine,Zudaire Enrique,Corsale Christina,Akram Muhammad,Geng Dong,Pacaud Lida,Sonneveld Pieter,Zweegman Sonja.Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTI

[6] Ferreri Christopher J.,Hildebrandt Michelle A.T.,Hashmi Hamza,Shune Leyla O.,McGuirk Joseph P.,Sborov Douglas W.,Wagner Charlotte B,Kocoglu M. Hakan,Atrash Shebli,Voorhees Peter M.,Khouri Jack,Dima Danai,Afrough Aimaz,Sannareddy Aishwarya,Simmons Gary,Davis James,Kalariya Nilesh,Peres Lauren C.,Alsina Melissa,Locke Frederick L.,Sidana Surbhi,Hansen Doris K.,Patel Krina,Castaneda Puglianini Omar Alexis.Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients wit

[7] Cohen Adam D,Mateos MariaVictoria,Cohen Yael C,RodriguezOtero Paula,Paiva Bruno,van de Donk Niels W C J,Martin Thomas G,Suvannasankha Attaya,De Braganca Kevin C,Corsale Christina,Schecter Jordan M,Varsos Helen,Deraedt William,Wang Liwei,Vogel Martin,Roccia Tito,Xu Xiaoying,Mistry Pankaj,Zudaire Enrique,Akram Muhammad,Nesheiwat Tonia,Pacaud Lida,Avivi Irit,SanMiguel Jesus.Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents[J].Blood,2022

[8] Dima Danai,Jiang Dongxu,Singh Divya Jyoti,Hasipek Metis,Shah Haikoo S.,Ullah Fauzia,Khouri Jack,Maciejewski Jaroslaw P.,Jha Babal K..Multiple Myeloma Therapy: Emerging Trends and Challenges[J].Cancers,2022

[9] Martin Thomas,Usmani Saad Z,Berdeja Jesus G,Agha Mounzer,Cohen Adam D,Hari Parameswaran,Avigan David,Deol Abhinav,Htut Myo,Lesokhin Alexander,Munshi Nikhil C,O'Donnell Elizabeth,Stewart A Keith,Schecter Jordan M,Goldberg Jenna D,Jackson Carolyn C,Yeh TzuMin,Banerjee Arnob,Allred Alicia,Zudaire Enrique,Deraedt William,Olyslager Yunsi,Zhou Changwei,Pacaud Lida,Madduri Deepu,Jakubowiak Andrzej,Lin Yi,Jagannath Sundar.Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Rece

[10] Dimopoulos Meletios A,Richardson Paul G,Bahlis Nizar J,Grosicki Sebastian,Cavo Michele,Beksaç Meral,Legieć Wojciech,Liberati Anna M,Goldschmidt Hartmut,Belch Andrew,Magen Hila,Larocca Alessandra,Laubach Jacob P,Petrucci Maria T,Reece Donna,White Darrell,Mateos MaríaVictoria,Špička Ivan,Lazaroiu Mihaela,Berdeja Jesús,Kaufman Jonathan L,Jou YingMing,Ganetsky Alex,Popa McKiver Mihaela,Lonial Sagar,Weisel Katja.Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnose

[1] Xia Jieyun,Li Hujun,Yan Zhiling,Zhou Dian,Wang Ying,Qi Yuekun,Cao Jiang,Li Depeng,Cheng Hai,Sang Wei,Zhu Feng,Sun Haiying,Chen Wei,Qi Kunming,Yan Dongmei,Qiu Tingting,Qiao Jianlin,Yao Ruosi,Liu Yang,Wang Xue,Zhang Yanlei,Peng Shuixiu,Huang ChihHua,Zheng Junnian,Li Zhenyu,Chang Alex H,Xu Kailin.Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial[J].Journal of clinical onco

[2] Dimopoulos Meletios A.,Dytfeld Dominik,Grosicki Sebastian,Moreau Philippe,Takezako Naoki,Hori Mitsuo,Leleu Xavier,LeBlanc Richard,Suzuki Kenshi,Raab Marc S.,Richardson Paul G.,Popa McKiver Mihaela,Jou Ying Ming,Yao David,Das Prianka,San Miguel Jesús.Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial[J].Journal of Clinical Oncology,2023

[3] Parikh Rujul H,Lonial Sagar.Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice[J].CA: a cancer journal for clinicians,2023

[4] Chari Ajai,Minnema Monique C.,Berdeja Jesus G.,Oriol Albert,van de Donk Niels W.C.J.,Rodríguez Otero Paula,Askari Elham,Mateos María Victoria,Costa Luciano J.,Caers Jo,Verona Raluca,Girgis Suzette,Yang Shiyi,Goldsmith Rachel B.,Yao Xiang,Pillarisetti Kodandaram,Hilder Brandi W.,Russell Jeffery,Goldberg Jenna D.,Krishnan Amrita.Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma[J].New England Journal of Medicine,2022

[5] Van De Donk Niels WCJ,Agha Mounzer,Cohen Adam D,Cohen Yael C,Anguille Sébastien,Kerre Tessa,Roeloffzen Wilfried W.H.,Schecter Jordan M,De Braganca Kevin C,Jackson Carolyn C,Varsos Helen,Mistry Pankaj,Roccia Tito,Xu Xiaoying,Li Katherine,Zudaire Enrique,Corsale Christina,Akram Muhammad,Geng Dong,Pacaud Lida,Sonneveld Pieter,Zweegman Sonja.Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTI

[6] Ferreri Christopher J.,Hildebrandt Michelle A.T.,Hashmi Hamza,Shune Leyla O.,McGuirk Joseph P.,Sborov Douglas W.,Wagner Charlotte B,Kocoglu M. Hakan,Atrash Shebli,Voorhees Peter M.,Khouri Jack,Dima Danai,Afrough Aimaz,Sannareddy Aishwarya,Simmons Gary,Davis James,Kalariya Nilesh,Peres Lauren C.,Alsina Melissa,Locke Frederick L.,Sidana Surbhi,Hansen Doris K.,Patel Krina,Castaneda Puglianini Omar Alexis.Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients wit

[7] Cohen Adam D,Mateos MariaVictoria,Cohen Yael C,RodriguezOtero Paula,Paiva Bruno,van de Donk Niels W C J,Martin Thomas G,Suvannasankha Attaya,De Braganca Kevin C,Corsale Christina,Schecter Jordan M,Varsos Helen,Deraedt William,Wang Liwei,Vogel Martin,Roccia Tito,Xu Xiaoying,Mistry Pankaj,Zudaire Enrique,Akram Muhammad,Nesheiwat Tonia,Pacaud Lida,Avivi Irit,SanMiguel Jesus.Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents[J].Blood,2022

[8] Dima Danai,Jiang Dongxu,Singh Divya Jyoti,Hasipek Metis,Shah Haikoo S.,Ullah Fauzia,Khouri Jack,Maciejewski Jaroslaw P.,Jha Babal K..Multiple Myeloma Therapy: Emerging Trends and Challenges[J].Cancers,2022

[9] Martin Thomas,Usmani Saad Z,Berdeja Jesus G,Agha Mounzer,Cohen Adam D,Hari Parameswaran,Avigan David,Deol Abhinav,Htut Myo,Lesokhin Alexander,Munshi Nikhil C,O'Donnell Elizabeth,Stewart A Keith,Schecter Jordan M,Goldberg Jenna D,Jackson Carolyn C,Yeh TzuMin,Banerjee Arnob,Allred Alicia,Zudaire Enrique,Deraedt William,Olyslager Yunsi,Zhou Changwei,Pacaud Lida,Madduri Deepu,Jakubowiak Andrzej,Lin Yi,Jagannath Sundar.Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Rece

[10] Dimopoulos Meletios A,Richardson Paul G,Bahlis Nizar J,Grosicki Sebastian,Cavo Michele,Beksaç Meral,Legieć Wojciech,Liberati Anna M,Goldschmidt Hartmut,Belch Andrew,Magen Hila,Larocca Alessandra,Laubach Jacob P,Petrucci Maria T,Reece Donna,White Darrell,Mateos MaríaVictoria,Špička Ivan,Lazaroiu Mihaela,Berdeja Jesús,Kaufman Jonathan L,Jou YingMing,Ganetsky Alex,Popa McKiver Mihaela,Lonial Sagar,Weisel Katja.Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnose